<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043012</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1044</org_study_id>
    <nct_id>NCT05043012</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)</brief_title>
  <official_title>Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically&#xD;
      significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen,&#xD;
      which can decrease the rate of unnecessary biopsies and reduce the incidence of&#xD;
      over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is more accurate in&#xD;
      detecting high-grade (Gleason grade group ≥3) versus low grade cancers (Gleason grade group&#xD;
      &lt;2) and therefore may serve as a useful adjunct to prostate-specific antigen (PSA) testing,&#xD;
      digital rectal examination, and prostatic biopsy to detect cancers that require definitive&#xD;
      treatment as opposed to active surveillance. Many investigators, including our group, have&#xD;
      shown the utility of preoperative mpMRI to assess the local extent of prostate cancer and for&#xD;
      surgical planning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare the detection rate of Gleason Group grade ≥ 2 disease in patients with&#xD;
      intermediate and high-risk prostate cancer who undergo ERC mpMRI (Group 1: Control) versus&#xD;
      patients who undergo non-ERC mpMRI with flexible AIR coil technology (Group 2: Experimental).&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        1. To compare the scanning time and room time in Group 1 versus Group 2.&#xD;
&#xD;
        2. To compare patient-reported outcome at the end of the MRI test in Group 1 versus Group 2&#xD;
           through testing morbidities index (TMI).&#xD;
&#xD;
        3. To determine the impact of mpMRI on treatment planning for men with intermediate and&#xD;
           high-risk prostate cancer and compare management impact in Group 1 versus Group 2&#xD;
&#xD;
        4. To compare the detection rate of T3 disease on MRI (confirmed by histopathology) at&#xD;
           prostatectomy between Group 1 versus Group 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate the detection rate of Gleason Group grade ≥ 2 disease in patients with intermediate and high-risk prostate cancer who undergo ERC mpMRI</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will have an mpMRI scan with a flexible AIR coil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will have an mpMRI scan with an endorectal coil</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>flexible AIR coil</intervention_name>
    <description>mpMRI scan</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endorectal coi</intervention_name>
    <description>mpMRI scan</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, Age ≥ 18&#xD;
&#xD;
          -  Untreated, biopsy-proven with intermediate and high-risk (Gleason group grade &gt;/=2)&#xD;
             adenocarcinoma of the prostate&#xD;
&#xD;
          -  Patient is being considered for curative-intent treatment with radical prostatectomy&#xD;
             within 6 months following mpMRI&#xD;
&#xD;
          -  Patient has provided written informed consent for participation in this trial&#xD;
&#xD;
          -  Patient should be eligible for scanning at 3 T magnet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low-risk adenocarcinoma of prostate&#xD;
&#xD;
          -  Patient has had any prior therapy for prostate cancer&#xD;
&#xD;
          -  A history of other active malignancy within the last 2 years&#xD;
&#xD;
          -  Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small&#xD;
             cell components&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Orthopedic hardware in the pelvis and spine.&#xD;
&#xD;
          -  Claustrophobia and/or receiving anesthesia&#xD;
&#xD;
          -  Contraindication for endorectal coil such as rectal bleeding, severe anal fissures or&#xD;
             hemorrhoids, anal/rectal surgery, and lack of rectum.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tharakeswara Bathala</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tharakeswara Bathala</last_name>
    <phone>713-792-2533</phone>
    <email>TKBathala@mdanderson.org</email>
  </overall_contact>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

